NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization165.58 mln
Float16.98 mln
Earnings Date05/13/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
72
/ 100
Outperforming
Debt / Equity
0.00
Debt-free
ROE
-52.12
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
AN2 Therapeutics is a drug development company based in Menlo Park, California, that uses its boron chemistry platform to create new treatments for infectious diseases and cancer. Its lead drug, epetraborole, is currently in late-stage clinical trials as a daily oral pill for patients with non-tuberculous mycobacterial lung disease and is also being explored as a treatment for acute melioidosis. The company has additional programs in early development, including a treatment for chronic Chagas disease, and holds licensing partnerships with Anacor Pharmaceuticals, Brii Biosciences, and GSK to support the development and commercialization of its compounds across multiple markets.
